Adcirca (previously Tadalafil Lilly)
Authorised
This medicine is authorised for use in the European Union
tadalafil
MedicineHumanAuthorised
Overview
Adcirca is a medicine used to treat adults and children from 2 years of age with pulmonary arterial hypertension (PAH).
PAH is a disease where there is abnormally high blood pressure in the arteries of the lungs. Adcirca is used in patients with PAH class II (where the patients have slight limitation of physical activity) and PAH class III (where patients have marked limitation of physical activity).
Adcirca contains the active substance tadalafil.
Adcirca is available as tablets and as a liquid to be taken by mouth. Both can only be obtained with a prescription. Treatment should only be started and monitored by a doctor who has experience in the treatment of PAH.
The recommended dose for adults is 40 mg once a day. For children the dose depends on the child’s weight. A lower starting dose is recommended in patients with mild or moderate kidney or liver problems. Adcirca is not recommended for patients with severe kidney or liver problems. For more information about using Adcirca, see the package leaflet or contact your healthcare provider.
PAH is a debilitating disease where there is severe narrowing of the blood vessels of the lungs. It causes high blood pressure in the vessels taking blood from the heart to the lungs. This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult.
The active substance in Adcirca, tadalafil, belongs to a group of medicines called ‘phosphodiesterase type 5 (PDE5) inhibitors’, which means that it blocks the PDE5 enzyme. This enzyme is found in the blood vessels of the lungs. When the enzyme is blocked, a substance called ‘cyclic guanosine monophosphate’ (cGMP) cannot be broken down and remains in the vessels where it causes the relaxation and widening of the blood vessels. In patients with PAH, this lowers the blood pressure in the lungs and improves symptoms.
Adcirca was more effective than placebo at improving exercise capacity based on one main study involving 406 patients with PAH, most of whom had class II or class III disease. Before treatment, these patients could walk an average of 343 metres in six minutes. After 16 weeks, this distance had increased by 26 metres more in the patients taking 40 mg Adcirca than in the patients taking placebo.
An additional study in 35 children with PAH also showed that treatment with Adcirca led to an improvement in the distance the children could walk in six minutes with Adcirca, which was consistent with that observed in adults.
The most common side effects with Adcirca (seen in more than 1 patient in 10) are headache, flushing (reddening of the skin), nasopharyngitis (inflammation of the nose and throat) including a blocked or runny nose and blocked sinuses, nausea (feeling sick), dyspepsia (heartburn)including abdominal (belly) pain or discomfort, myalgia (muscle pain), back pain and pain in the extremities (arms, hands, legs and feet).
Adcirca must not be used in patients who have had an acute myocardial infarction (sudden heart attack) within the last three months, or who have severe hypotension (low blood pressure). Adcirca must not be taken with nitrates (a group of medicines used to treat angina) or medicines of the class ‘guanylate cyclase stimulators’ such as riociguat (another medicine to treat pulmonary hypertension). It must not be used in patients who have ever had loss of vision because of a problem called non-arteritic anterior ischaemic optic neuropathy (NAION) that affects the blood flow to the nerve in the eye.
For the full list of all side effects and restrictions with Adcirca, see the package leaflet.
The European Medicines Agency decided that Adcirca’s benefits are greater than its risks and it can be authorised for use in the EU. Studies show that Adcirca improved walking ability in adults and children, and the side effects are manageable.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Adcirca have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Adcirca are continuously monitored. Suspected side effects reported with Adcirca are carefully evaluated and any necessary action taken to protect patients.
Adcirca received a marketing authorisation valid throughout the EU on 1 October 2008. This authorisation was based on the authorisation granted to Cialis in 2002 (‘informed consent’). The name of the medicine was changed to Adcirca on 21 October 2009.
Product information
Latest procedure affecting product information: PSUSA/00002841/202210
01/09/2023
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Adcirca (previously Tadalafil Lilly)
- Active substance
- tadalafil
- International non-proprietary name (INN) or common name
- tadalafil
- Therapeutic area (MeSH)
- Hypertension, Pulmonary
- Anatomical therapeutic chemical (ATC) code
- G04BE08
Pharmacotherapeutic group
UrologicalsTherapeutic indication
Adults
Treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).
Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.
Paediatric population
Treatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.
News on Adcirca (previously Tadalafil Lilly)
Topics
This page was last updated on